Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Webster

Showing results (951-960 of 996) with videos related to

Pageof 100
Sort By:
JCO Clinical Cancer Informatics|December 10, 2025
Patient Portal Engagement in Oncology: Results From the NU IMPACT Study in a Large Health Care SystemKyle M Nolla, Maja Kuharic, Nicola Lancki, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
The Lancet. Infectious Diseases|December 21, 2024
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection studyBenoit Bestgen, Sam Jones, Vandana Thathy, et al.
Plos One|January 25, 2021
Development of a porcine model of phenylketonuria with a humanized R408W mutation for gene editingRobert A Kaiser, Daniel F Carlson, Kari L Allen, et al.
Cancer|October 4, 2025
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical careLisa M Gudenkauf, Danielle B Tometich, Aasha I Hoogland, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy AdultsM Farouk Chughlay, Karen I Barnes, Myriam El Gaaloul, et al.
Nature Genetics|September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Plos One|September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuriaJohn Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
Pageof 100

Showing results (951-960 of 996) with videos related to

Sort By:
Pageof 100
JCO Clinical Cancer Informatics|December 10, 2025
Patient Portal Engagement in Oncology: Results From the NU IMPACT Study in a Large Health Care SystemKyle M Nolla, Maja Kuharic, Nicola Lancki, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
The Lancet. Infectious Diseases|December 21, 2024
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection studyBenoit Bestgen, Sam Jones, Vandana Thathy, et al.
Plos One|January 25, 2021
Development of a porcine model of phenylketonuria with a humanized R408W mutation for gene editingRobert A Kaiser, Daniel F Carlson, Kari L Allen, et al.
Cancer|October 4, 2025
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical careLisa M Gudenkauf, Danielle B Tometich, Aasha I Hoogland, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy AdultsM Farouk Chughlay, Karen I Barnes, Myriam El Gaaloul, et al.
Nature Genetics|September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Plos One|September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuriaJohn Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
Pageof 100